Biogen details Leqembi's gradual commercial ramp-up
Biogen recorded higher-than-expected revenue for the lead rare disease drug from its $7 billion acquisition of Reata Pharmaceuticals, but the rollout of its second-generation Alzheimer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.